ライフサイエンスコーパス: ADC

1 ADC and D(app) were lower and K(app) was higher in malig

2 ADC and renal hypoxia (R2*) by blood-oxygen-level-depend

3 ADC inversely correlated with the histological degree of

4 ADC mapping showed evidence of ischemia as early as 27 m

5 ADC maps were computed from DW-MRI.

6 ADC maturation occurred earlier in the left hemisphere (

7 ADC maturation was completed between 1.3 and 2.4 years o

8 ADC percentiles correlated negatively with tumor growth

9 ADC values below the cut-off was 97.1%, specificity was

10 ADC values of thalami, CN, and CH were significantly low

11 ADC values showed significant differences between benign

12 ADC values were measured in different brain regions and

13 ADC(L) values were correlated to available RNA expressio

14 lung ADCs.Methods: DNA was extracted from 21 ADCs in situ (AISs), 27 minimally invasive ADCs (MIAs),

15 ncrease of the ADC values (ADC(min), +29.4%; ADC(mean), +32.8%).

16 cyclic Ge(I) compound [(ADC(Ph))Ge](2) (4) (ADC(Ph) = {CN(Dipp)}(2)CPh, Dipp = 2,6-iPr(2)C(6)H(3)) c

17 ted) and mild emphysema (normal CT, abnormal ADC) were negatively correlated with FEV(1) (r = -0.65 a

18 ed by the more rapid clearance of the Active ADC, while exhibiting minimal deconjugation of the pyrro

19 efficient generation of functionally active ADCs.

20 cular underpinnings of early adenocarcinoma (ADC) progression.

21 eported clinical benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though

22 Although ADC linkers can be 'non-cleavable', the vast majority of

23 Among ADC metrics tested, none improved diagnostic performance

24 ROC curve analysis determined an ADC value of 958 x 10(-6) mm(2)/s to be able to differen

25 Sacituzumab govitecan (SG) is an ADC composed of a Trop-2-targeted antibody conjugated to

26 ata indicate that targeting CLDN18.2 with an ADC or bispecific modality could be a valid therapeutic

27 es accordingly with the GlcN6P biosensor and ADC system enabled feedback circuits, the metabolic flux

28 v(e) and ADC did not show any statistical significance.

29 signal greater than that in endometrium, and ADC less than or equal to 0.905 x 10(-3) mm(2)/sec.

30 used to evaluate both MR fingerprinting and ADC in differentiating NTZ, cancers and noncancers, clin

31 ontrast T1-weighted, T2-weighted, FLAIR, and ADC images as well as two engineered sequences; T1post-T

32 egative correlation between PET-SUV(max) and ADC values of lung lesions.

33 ficant positive correlation between nSUV and ADC only in voxelwise analysis (r (voxelwise) = 0.18).

34 between the normalized SUV (nSUV), rCBV, and ADC were evaluated.

35 000 s/mm(2), DWI signal intensity scores and ADC values are effective methods for the differential di

36 0.01), whereas differences in tumor size and ADC(min) did not (>0.05).

37 , the repeatability of the evaluated SUV and ADC metrics on (18)F-FDG PET/MRI is both acceptably high

38 , and +14.6% in ADC(mean) Changes in SUV and ADC(mean) significantly differed between responders and

39 MRI-derived quantitative parameters (SUV and ADC(mean)) and their combination performed well in predi

40 ween the standardized uptake value (SUV) and ADC data corrected for distortion were computed from opt

41 mm(2)/sec, respectively; P = .001 for T1 and ADC and P = .03 for T2).

42 The T1, T2, and ADC in cancers were lower than those in noncancers (1620

43 els compared two-reader means of T1, T2, and ADC.

44 Combined TBF and ADC for peritumoural regions revealed an AUC of 0.96 and

45 TBF and ADC of tumoural and peritumoural regions are accurate no

46 Combined TBF and ADC of tumoural regions revealed an AUC of 0.808 and acc

47 the desalting or buffer-exchange of mAbs and ADCs samples.

48 lutions for monoclonal antibodies (mAbs) and ADCs, such as nonvolatile phosphate-buffered saline (PBS

49 les of the corresponding clinically approved ADC Kadcyla.

50 herefore, we recommend that using compost as ADC be considered, especially when site-specific factors

51 tions for fertilizer and peat, to its use as ADC.

52 ce of gross tumour volume changes as well as ADC and kurtosis models.

53 rent reduction strategy is applied to assess ADC subunits in both the partially reduced (intrachain d

54 red the longest dimension and lesion-average ADC on three DWI methods, reported measurement confidenc

55 ate pre-operative ADC(L) values, the average ADC in the lower distribution using a double Gaussian mi

56 Basal ADC values correlated modestly with change in SBP, but n

57 Baseline ADC values were correlated with changes in eGFR, serum c

58 of variance) testing of associations between ADC metrics and glioma genotypes, including Bonferroni c

59 re was a positive linear correlation between ADC(L) levels and DCN protein expression between tumors

60 as used to investigate relationships between ADC (histogram parameters) and tumor size at baseline wi

61 umors, voxelwise correlations (r(s)) between ADC and SUV revealed null or weak monotonic relationship

62 aluate for DCN RNA and protein expression by ADC value.

63 Centralized ADC measures were performed, including manually drawn wh

64 tially opens up a new avenue to characterize ADCs.

65 e points and apparent diffusion coefficient (ADC) at baseline was calculated by using segmentations b

66 Apparent diffusion coefficient (ADC) calculation and kurtosis fitting were performed.

67 culations of apparent diffusion coefficient (ADC) can help further improve diagnostic performance ver

68 ns of normal apparent diffusion coefficient (ADC) development from 0 to 6 years of age.

69 st that high apparent diffusion coefficient (ADC) distinguishes meningioma regions with proliferating

70 sessment and apparent diffusion coefficient (ADC) histogram analyses were performed for the first tim

71 suggest that apparent diffusion coefficient (ADC) imaging phenotypes predict survival response to ant

72 between the apparent diffusion coefficient (ADC) maps (denoised vs reference) was analyzed using Bla

73 c/mm(2), and apparent diffusion coefficient (ADC) maps from the three randomly labeled DWI methods.

74 Apparent diffusion coefficient (ADC) minimum (ADC(min)) and mean (ADC(mean)) regions of

75 ow (TBF) and apparent diffusion coefficient (ADC) of the tumoral and peritumoural regions was made.

76 ensional SUV apparent diffusion coefficient (ADC) parameters and arterial tumor enhancement were test

77 rformance of apparent diffusion coefficient (ADC) quantification compared with T1 and T2 values in th

78 matching and apparent diffusion coefficient (ADC) regional map computation were assessed.

79 's (DWI-MRI) apparent diffusion coefficient (ADC) reveals water diffusion is unobstructed by microstr

80 increase in apparent diffusion coefficient (ADC) value between MR1 and MR2 was higher in the pCR gro

81 calculating apparent diffusion coefficient (ADC) values and image quality parameters (signal-to-nois

82 compare the apparent diffusion coefficient (ADC) values of different brain areas between two groups

83 sed, and the apparent diffusion coefficient (ADC) values of the lesions were calculated.

84 nd threshold apparent diffusion coefficient (ADC) values that can aid in the differentiation of malig

85 ) signal and apparent diffusion coefficient (ADC) values was developed to predict for sarcoma.

86 nd medullary apparent diffusion coefficient (ADC) values.

87 e (rCBV) and apparent diffusion coefficient (ADC), in gliomas with different molecular subtypes and t

88 tracted from apparent diffusion coefficient (ADC)-maps is essential for reliable correlation with the

89 CT, abnormal apparent diffusion coefficient [ADC]: 33% vs 54%, 56%, and 54% for GOLD I, II, and III/I

90 restriction (apparent diffusion coefficient, ADC) were determined in pre- and posttherapeutic examina

91 nimum tumor apparent diffusion coefficients (ADCs) and maximum standardized uptake value (SUV) of up

92 The cyclic Ge(I) compound [(ADC(Ph))Ge](2) (4) (ADC(Ph) = {CN(Dipp)}(2)CPh, Dipp = 2

93 zumab govitecan, an antibody-drug conjugate (ADC) comprised of a humanized anti- Trop-2 antibody, con

94 Conventional antibody-drug conjugate (ADC) manufacturing methods are based on the nonselective

95 odalities, such as antibody-drug conjugates (ADC), present significant challenges for the comprehensi

96 rrent FDA-approved antibody-drug conjugates (ADC).

97 n tumor sites from antibody-drug conjugates (ADCs) and caged prodrugs.

98 molecule payload, antibody-drug conjugates (ADCs) are administered at a much lower dose than their p

99 Antibody-drug conjugates (ADCs) are an increasingly prevalent drug class utilized

100 in cysteine linked antibody-drug conjugates (ADCs) are emerging therapeutic products that antagonize

101 While antibody-drug conjugates (ADCs) are now clinically established for cancer therapy,

102 he construction of antibody-drug conjugates (ADCs) as the ultimate goal of this research program.

103 Antibody drug conjugates (ADCs) can undergo in vivo biotransformation (e.g., paylo

104 d in the field for antibody drug conjugates (ADCs) containing peptide linkers that are enzymatically

105 Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deli

106 In vitro, these antibody drug conjugates (ADCs) exhibited significant cytotoxic and target-mediate

107 Antibody-drug conjugates (ADCs) harness the highly specific targeting capabilities

108 Antibody-drug conjugates (ADCs) have become a major class of oncology biopharmaceu

109 Antibody-drug conjugates (ADCs) have gained significant interest over the past few

110 Antibody-drug conjugates (ADCs) have recently gained traction in the biomedical co

111 Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin

112 haracterization of antibody-drug conjugates (ADCs) using mass spectrometry (MS) is important in drug

113 ecific antibodies, antibody drug conjugates (ADCs), and combination therapies.

114 Antibody drug conjugates (ADCs), which harness the high targeting specificity of m

115 the preparation of antibody-drug conjugates (ADCs).

116 otoxic payloads in antibody-drug conjugates (ADCs).

117 ion of pro-angiogenic signaling, may connect ADC phenotypes to survival benefit to anti-VEGF therapy.

118 The average daily consumption (ADC) of cigarettes by groups 1 and 3 were higher than th

119 xposure (MLE) and average daily consumption (ADC) relating to two commercially available tobacco heat

120 work, we created an autonomous dual-control (ADC) system, by combining CRISPRi-based NOT gates with n

121 tibody, and sacituzumab govitecan vs control-ADC, respectively).

122 post may be used as alternative daily cover (ADC) in landfills.

123 y to other drugs targeting CXCR4, anti-CXCR4 ADCs effectively eliminated cancer cells as monotherapy,

124 Differences in ADC, kurtosis-derived ADC (D(app)), and apparent kurtosis coefficient (K(app))

125 es in tumor perfusion and water diffusivity (ADC) using dynamic contrast-enhanced MRI (DCE-MRI) and d

126 albumin-binding domain to the single-domain ADCs.

127 sitivity and specificity with the help of DW-ADC maps.

128 MUSE DWI ADC values showed a significant difference between malig

129 E-MRI (v(e), v(p), PS, F(p), K(trans)), DWI (ADC) and PET (K(i), K(1), k(2), k(3)) to assess if an in

130 s estimated according to thresholds for each ADC metric.

131 We hypothesized that the behavior of early ADC can be predicted based on genomic determinants.Objec

132 classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use.

133 iety represents a novel approach to enediyne ADC creation, while the pharmacological profiles of at l

134 gments has been extensively used to evaluate ADC biotransformation.

135 for SUV(peak), 0.82 for SUV(mean), 0.63 for ADC(min), 0.84 for ADC(mean), and 0.89 for ratio of ADC(

136 2 for SUV(mean), 0.63 for ADC(min), 0.84 for ADC(mean), and 0.89 for ratio of ADC(mean) to SUV(peak)

137 ver operating characteristic curve (AUC) for ADC, D(app), and K(app) to discriminate malignant from b

138 Crucial metrics for ADC efficacy, safety, and selectivity are their drug-ant

139 ast free-breathing acquisition technique for ADC mapping (approximate duration, 3 minutes; five slice

140 ations will augment the existing toolbox for ADC characterization, particularly to enable the rapid o

141 c stability has been previously reported for ADCs in vivo.

142 A typical bioanalytical strategy for ADCs involves quantification of the Total ADC, Total IgG

143 Thus, the bioanalytical strategy for ADCs must be designed to address the specific structural

144 al: 0.77, 0.94) was higher than was AUC from ADC of 0.78 (95% confidence interval: 0.67, 0.89; P = .0

145 SUV and functional ADCs, as well as arterial contrast enhancement parameter

146 selection of promising candidates for future ADC development.

147 al profiles of at least two of the generated ADCs compare well with the profiles of the corresponding

148 Whilst early generation ADCs were primarily synthesised as heterogeneous mixture

149 f antibody-TNM conjugates as next-generation ADCs for targeted chemotherapy.

150 le the rapid optimization of DAR for a given ADC and thus better understand its potential toxicity an

151 hildren: Severe hypoxia, evidenced by global ADC decrease and elevated plasma levels of lipocalin-2 a

152 junct with relatively high diffusivity (high ADC values) suggesting diagnosis of alveolar hydatid.

153 ion levels were significantly larger in high ADC(L) tumors (41.6 vs. 1.5; P = 0.0081).

154 id model of meningioma and validate the high ADC marker genes CDH2 and PTPRZ1 as potential targets fo

155 Homogeneous ADCs have repeatedly demonstrated superior overall pharm

156 that result in the generation of homogeneous ADCs.

157 ane antigen-binding single-domain (Humabody) ADC constructs to demonstrate that tissue penetration of

158 to yield the elusive bis-hydridogermylene [(ADC(Ph))GeH](2) (5).

159 methods for disulfide-linked self-immolating ADCs are lacking as they are a different conjugation mod

160 in SUV(peak), -13.9% in SUV(mean), +15.3% in ADC(min), and +14.6% in ADC(mean) Changes in SUV and ADC

161 SUV(mean), +15.3% in ADC(min), and +14.6% in ADC(mean) Changes in SUV and ADC(mean) significantly dif

162 Hemispheric asymmetries in ADC maturation ages were assessed using t tests with Bon

163 er, there were no significant differences in ADC values between IUGR subtypes.

164 There were no significant differences in ADC when comparing the same product between different gr

165 Differences in ADC, kurtosis-derived ADC (D(app)), and apparent kurtosi

166 ow that tumor fibrosis is actually higher in ADC-TAFs than SCC-TAFs in vitro and patient samples.

167 and T1C (p = 0.0004), and lower intensity in ADC (p = 0.029) and DTI-p (p = 0.001) compared to non-pr

168 ng fibrotic phenotype of TAFs selectively in ADC.

169 , whereas genetic downregulation of SMAD3 in ADC-TAFs and control fibroblasts increased TGFbeta1/SMAD

170 rror model that estimated the uncertainty in ADC repeatability measurements therefore taking into con

171 of Medical Sciences (CAMS), and validated in ADC patients from the National Lung Screening Trial (NLS

172 Two predictive models incorporating ADC(mean)-to-ADC(NAWM) ratio, age, and morphologic chara

173 Increased ADC(L) on diffusion MR imaging is associated with high D

174 23 x10(3)mum(2)/sec) demonstrate low initial ADC values, indicating an earlier prenatal time course o

175 Furthermore, by reducing the size of intact ADC (~150 kDa) to subfragments (~25 kDa), the identifica

176 Affinity capture LC-MS of intact ADCs or ADC subfragments has been extensively used to ev

177 the optimal molecular design of the intended ADCs as targeted cancer therapies.

178 burden was significantly greater in invasive ADC, whereas more copy number loss was observed in AIS a

179 invasive ADCs (MIAs), and 54 fully invasive ADCs.

180 1 ADCs in situ (AISs), 27 minimally invasive ADCs (MIAs), and 54 fully invasive ADCs.

181 terchain disulfide bonds to generate ~25 kDa ADC subfragments, which are finally analyzed by LC-HRMS

182 DWI was post-processed using kurtosis (ADC(k), K), mono- (ADC(m)), and biexponential functions

183 Specifically, a model cysteine-linked ADC was reduced to generate six unique subunits: light c

184 tional isomers of interchain cysteine linked ADCs.

185 Disulfide-linked ADCs captured from plasma were chemically reduced at bas

186 assays for next-generation disulfide-linked ADCs involving immunoaffinity capture, chemical cleavage

187 Lower ADC potentially reflects renal injury in RVD patients, b

188 Lower ADC values demonstrated stronger correlations.

189 Among all brain regions, pons had the lowest ADC values.

190 s associated with poor outcome in early lung ADC, with potential future implications for the detectio

191 logy images from a cohort of 91 stage I lung ADC patients from the Chinese Academy of Medical Science

192 resected indolent and aggressive early lung ADCs.Methods: DNA was extracted from 21 ADCs in situ (AI

193 in tumor and normal appearing white matter (ADC(NAWM)).

194 0.79 vs AUC, 0.75; P = .02-.84), and maximum ADC had worse performance (AUC, 0.52; P < .001).

195 Mean ADC values were 1.74 +/- 0.48 x 10(-3) mm(2)/s (range: 1

196 Mean ADC was markedly high in the infarcted regions (2.32 x 1

197 posterior limb of the internal capsule (mean ADC: left hemisphere, 1.18 x10(3)mum(2)/sec; right hemis

198 appa scores of 0.89, 0.82, and 0.93 for mean ADC, baseline tumor volume, and follow-up tumor volume,

199 In remote regions, mean ADC (1.62 x10(-3) mm(2)/sec; 95% CI: 1.59, 1.64) was com

200 diagnostic performance versus standard mean ADC (AUC, 0.59-0.79 vs AUC, 0.75; P = .02-.84), and maxi

201 The mean ADC of lacrimal glands in thyroid eye disease (1.73 x 10

202 The mean ADC value for atypical haemangiomas was 1884 +/- 74 x 10

203 The mean ADC value of benign pathologies was significantly greate

204 greement with the reference ADC values (mean ADC difference ranged from -0.04 to 0.02 x 10(-3) mm(2)/

205 r improve diagnostic performance versus mean ADC values alone for analysis of suspicious breast lesio

206 efficient (ADC) minimum (ADC(min)) and mean (ADC(mean)) regions of interest were defined in tumor and

207 the combined ratio of PET/MRI and SUV(mean)/ADC(min) may be used as a novel biomarker allowing diffe

208 app) was higher in malignant lesions: median ADC, D(app), and K(app) were 0.74 um(2)/msec (range, 0.5

209 ximum or median nSUV, median rCBV, or median ADC.

210 I: 0.70, 0.88), and a threshold using median ADC provided the greatest reduction in biopsy rate of 23

211 eport focused more on the use of the minimal ADC (mADC) value on the solid component, to differentiat

212 idence interval [CI]: 99%, 100%) and minimum ADC (area under the receiver operating characteristic cu

213 e-shot DWI in the mean, maximum, and minimum ADC values (P = .96, P = .28, and P = .49, respectively)

214 unctional tumor volume, and mean and minimum ADC were measured on the basis of volumes of interest an

215 d diffusion-weighted imaging-derived minimum ADC was introduced as a combined variable to predict tum

216 Differences in minimum ADC and maximum SUV between responders and nonresponders

217 pparent diffusion coefficient (ADC) minimum (ADC(min)) and mean (ADC(mean)) regions of interest were

218 processed using kurtosis (ADC(k), K), mono- (ADC(m)), and biexponential functions (f, D(p), D(f)) whi

219 Nevertheless, ADC conjugation techniques and processes may introduce i

220 Nine ADCs have received approval from the US Food and Drug Ad

221 Additionally, a noninternalizing ADC built with a pentynoyl traceless linker that feature

222 s of interest, histogram metrics, normalized ADC, and variable b-value combinations.

223 rization of the PK and catabolism of a novel ADC.

224 These novel ADCs displayed sub-nanomolar cytotoxicity against HER2-e

225 : ADC trajectory, rate of ADC change, age of ADC maturation, and hemispheric asymmetries of maturatio

226 In the course of ADC generation and in vitro evaluation, we identified tw

227 ications for the detection and management of ADC.

228 and 1.36 x 10(-3) mm(2)/s as the cut-off of ADC of tumoural and peritumoural regions was made, to di

229 ntify four patterns: ADC trajectory, rate of ADC change, age of ADC maturation, and hemispheric asymm

230 ), 0.84 for ADC(mean), and 0.89 for ratio of ADC(mean) to SUV(peak) Conclusion: PET- and MRI-derived

231 timized protocol allowed for 88% recovery of ADC at a 25 muL sample volume and 90% recovery at 100 mu

232 e needed to evaluate the prognostic value of ADC changes in IUGR foetuses.

233 n, enabling rapid multiattribute analysis of ADCs.

234 he in vitro and in vivo biotransformation of ADCs conjugated at different sites (LC, HC-Fab, and HC-F

235 eps: (1) "mono capture" or "dual capture" of ADCs from serum with streptavidin magnetic beads coated

236 antibodies, middle-down characterization of ADCs has been limited by the high complexity of the drug

237 ) is a powerful tool for characterization of ADCs.

238 The complexity of ADCs, including their large size, array of drug conjugat

239 , we present a novel method for desalting of ADCs and mAbs building on the SP3 approach with nonfunct

240 nitored to ensure the safety and efficacy of ADCs.

241 can be 'non-cleavable', the vast majority of ADCs in clinical development have specific release mecha

242 strategy to improve the tumor penetration of ADCs.

243 tic analysis was used to determine a cut-off ADC value to differentiate these lesions.

244 Targeted biopsies were selected based on ADC values and prospectively collected during resection.

245 tion of payload-linker can have an effect on ADC stability and hence needs to be carefully optimized.

246 n a cohort of 35 patients with pre-operative ADC imaging and surgical specimens, DCN RNA expression l

247 imaging analyzed to calculate pre-operative ADC(L) values, the average ADC in the lower distribution

248 The optimal ADC bears a non-cleavable linker, auristatin as payload

249 tween nSUV and rCBV (hazard ratio, 28.82) or ADC (hazard ratio, 0.085) had significant associations w

250 Affinity capture LC-MS of intact ADCs or ADC subfragments has been extensively used to evaluate A

251 ronger correlations between nSUV and rCBV or ADC may result in a worse prognosis for IDH(wt) gliomas.

252 at in the areas of affected renal parenchyma ADC values were consistently lower compared to unaffecte

253 tal were analyzed to quantify four patterns: ADC trajectory, rate of ADC change, age of ADC maturatio

254 and in determining dosing rate of PEGylated ADCs.

255 The 25th percentile ADC had the strongest correlation with growth rate (rho

256 The 25th-percentile ADC metric provided the best performance (AUC, 0.79; 95%

257 Quantitative ADC and unenhanced T1 and T2 values were compared in inf

258 In fatal cases, quantitative ADC histogram analyses also demonstrated different end-s

259 C-MS/MS method for rapid analysis of reduced ADCs without digestion, enabling determination of DAR, c

260 es were in good agreement with the reference ADC values (mean ADC difference ranged from -0.04 to 0.0

261 oups 1 and 3 were higher than the respective ADCs of both THP consumables.

262 Methods Previously constructed age-specific ADC atlases from 201 healthy full-term children (108 mal

263 e the biotransformation of any site-specific ADC independent of antibody type and site of conjugation

264 lity attributes of these novel site-specific ADC products.

265 We hypothesized that ADC may indicate renal injury and response to therapy in

266 The ADC maps are estimated for a user-defined region of inte

267 The ADC scenario outperforms the soil amendment scenario in

268 The ADC values based on the denoised hb DW images were in go

269 The ADC values of normal and pathological vertebrae were est

270 In comparison to the normal group, the ADC values in IUGR foetuses were significantly lower in

271 However, the ADC value of lymph nodes showing thickened cortex due to

272 was small but significant difference in the ADC of tumoural and peritumoural regions between grade I

273 After chemical reduction of the ADC and a subsequent 31.5 m SLIM IMS separation, the var

274 Predictive performance of the ADC parameter with highest correlation and tumor size at

275 cantly affect the safety and efficacy of the ADC product.

276 lization of the drug conjugation site of the ADC using high-resolution Fourier transform ion cyclotro

277 ean), -43.8%), as well as an increase of the ADC values (ADC(min), +29.4%; ADC(mean), +32.8%).

278 d in these models after a single dose of the ADC-46 (0.02 mumol/kg).

279 coverages of 60-80% for each subunit of the ADC.

280 e, and calculation of the overall DAR of the ADC.

281 on provided accurate mass information on the ADC subunits and facilitated the DAR determination of 2.

282 Conjugate PK assay strategies for these ADCs involve cleavage with cathepsin B or papain to rele

283 The pharmacokinetics and efficacy of these ADCs were further evaluated in gastric and lung cancer x

284 vertebrae were estimated, and the threshold ADC values were computed by receiver operating character

285 These parameters were compared to ADC and kurtosis diffusion models, and, measures from hi

286 to increase in frequency from AIS and MIA to ADC.

287 predictive models incorporating ADC(mean)-to-ADC(NAWM) ratio, age, and morphologic characteristics, w

288 or ADCs involves quantification of the Total ADC, Total IgG, and Free Warhead concentrations.

289 he management of urachal adenocarcinoma (UrC-ADC).

290 Results: Of 21 patients with UrC-ADC before (18)F-FDG PET/CT, Mayo staging was I/II in 8,

291 CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on

292 retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was pe

293 erences among regions was greater when using ADC.

294 ), as well as an increase of the ADC values (ADC(min), +29.4%; ADC(mean), +32.8%).

295 noted, and their apparent diffusion values (ADC) were calculated.

296 ugh the APOBEC signature was associated with ADC and poor survival.

297 eta transcription factor SMAD3 compared with ADC-TAFs, which elicited a compensatory increase in TGFb

298 respectively) and negative correlations with ADC (r (voxelwise) = -0.19 and -0.19, respectively; r (p

299 ver, our findings support that patients with ADC may be more responsive to antifibrotic drugs targeti

300 danib in SCC and supports that patients with ADC may benefit from antifibrotic drugs targeting stroma